German biotech firm Pacifico Biolabs has secured €7 million in a Series A funding round backed by Stray Dog Capital, TGFS Technologiegründerfonds Sachsen, Sprout & About Ventures, Simon Capital, FoodLabs, and a regional brewery partner.
- Founded in 2022, Pacifico Biolabs develops alternative protein ingredients using mycelium fermentation. Its core product line, Viando, includes a chicken alternative designed for industrial food manufacturers and foodservice operators.
- The production process is based on cultivating fungal mycelium in steel bioreactors, where microorganisms convert sugar-based feedstocks into protein-rich biomass.
- This method is designed to create structured, meat-like textures that replicate the taste, texture, and functionality of conventional animal meat.
- The resulting ingredients are intended as drop-in solutions for existing meat supply chains, requiring minimal changes to manufacturing or distribution systems.
Details of the deal
- The Series A will support the scaling of production through existing brewery infrastructure, expansion of the team, and acceleration of product development and commercial rollout. The company plans to use the funding to move toward industrial-scale manufacturing and prepare for retail launch across Europe, targeting market entry by late 2026.
